دورية أكاديمية
Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
| العنوان: | Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? |
|---|---|
| المؤلفون: | Martin-Lluesma S; Center of Experimental Therapeutics, Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland., Graciotti M; Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne 1011, Switzerland., Grimm AJ; Center of Experimental Therapeutics, Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland., Boudousquié C; Center of Experimental Therapeutics, Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland., Chiang CL; Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne 1011, Switzerland., Kandalaft LE; Center of Experimental Therapeutics, Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland; Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne 1011, Switzerland. Electronic address: Lana.Kandalaft@chuv.ch. |
| المصدر: | Current opinion in biotechnology [Curr Opin Biotechnol] 2020 Oct; Vol. 65, pp. 190-196. Date of Electronic Publication: 2020 Apr 22. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9100492 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0429 (Electronic) Linking ISSN: 09581669 NLM ISO Abbreviation: Curr Opin Biotechnol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Elsevier Original Publication: London : Current Biology, c1990- |
| مواضيع طبية MeSH: | Cancer Vaccines*/therapeutic use , Ovarian Neoplasms*/therapy , Vaccines*, Dendritic Cells ; Female ; Humans ; Immunotherapy |
| مستخلص: | New treatments are urgently needed in patients with ovarian cancer (OC), as diagnosis is delayed in many instances, resulting in 85% recurrence of the disease following surgery and standard chemotherapy. OC is considered to be an immunological type of cancer, despite its limited response to current immunotherapy options, including vaccination. Thus, additional interventions may improve their efficacy. Dendritic cells (DCs) are the most widely used cellular vaccination therapy in patients with OC due to their crucial role in the initiation and development of immune response. There are viable options for DC-vaccination with a favorable toxicity profile, but specific alternatives should consider the limited therapeutic effectiveness of DC-vaccination in OC treatment. In this respect, B-cells and macrophages provide additional possibilities that may be explored for immunotherapy. Here we consider the current state-of-the-art of immunotherapy strategies for OC treatment and evaluate their potential for future improvements. (Copyright © 2020 Elsevier Ltd. All rights reserved.) |
| المشرفين على المادة: | 0 (Cancer Vaccines) 0 (Vaccines) |
| تواريخ الأحداث: | Date Created: 20200426 Date Completed: 20210301 Latest Revision: 20210301 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.copbio.2020.03.003 |
| PMID: | 32334152 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0429 |
|---|---|
| DOI: | 10.1016/j.copbio.2020.03.003 |